Synendos Therapeutics expands Series A round

Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million.

20 April 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles